Overview

Phase I Study to Investigate the Alcohol Interaction of DA8159

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
Male
Summary
This study is designed to to investigate the effects of alcohol on the pharmacokinetics of Udenafil tablet in healthy male volunteers
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Asan Medical Center
Collaborator:
Dong-A Pharmaceutical Co., Ltd.
Treatments:
Ethanol
Udenafil
Criteria
Inclusion Criteria:

- Adult males aged 19 to 55 years at screening.

- Subjects with body weight ≥ 55 kg and within ±20% of the ideal body weight : Ideal
body weight = (height [cm] - 100)x0.9.

- Subjects who have received and understood completely the information regarding the
current study and given written informed consents to voluntarily participate in the
study and followed all instructions specified in the protocol.

Exclusion Criteria:

- Subjects with the test results of QTc > 430 ms or non-sinus cardiac rhythm by ECG
analysis.

- Subjects with hypotension or hypertension.

- Subjects who have drunken habitually (exceeding 21 units/week, 1 unit = 10 g of pure
alcohol) or who are unable to abstain from drinking during the study period from 2
days prior to the first administration of investigational product and during this
study.

- Subjects deemed ineligible by investigator based on other reasons, including abnormal
laboratory values or diseases.